Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 4/20 | 0.36 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 2/20 | 0.35 |
| ▸ | NME2 | P22392 | 1/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | ICMT | O60725 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2901598 | 0.93 | GAA (0.48) | GAAGSK3BFLT3PRKCATSHR | |
| SCHEMBL2905932 | 0.87 | GAA (0.52) | GAAGSK3BPRKCATSHRKDM4E | |
| SCHEMBL2904581 | 0.83 | GAA (0.47) | GAAGSK3BFLT3PDK1FGFR1 | |
| Iodide SCHEMBL3997829 | 0.82 | GAA (0.47) | GAAGSK3BFLT3PDK1FGFR1 | |
| SCHEMBL2904842 | 0.82 | GAA (0.48) | GAAGSK3BPRKCATSHRICMT | |
| SCHEMBL2902498 | 0.81 | KAT2B (0.43) | GAAGSK3BPRKCAKDM4EALDH1A1 | |
| SCHEMBL2902665 | 0.77 | GAA (0.49) | GAAGSK3BPRKCATSHRKDM4E | |
| SCHEMBL2901399 | 0.73 | GAA (0.56) | GAATSHRFGFR1SRCKDM4E | |
| SCHEMBL2901858 | 0.72 | GAA (0.63) | GAATSHRKDM4EALDH1A1 | |
| SCHEMBL2907735 | 0.71 | GAA (0.54) | GAATSHRTERTFGFR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874761-B1 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | claimed |
| EP-1874761-B1 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | AVENTIS PHARMA SA (FR) | 2010-08-18 | — | — | EP | disclosed |
| US-7517881-B2 | Triazine derivatives, their preparation and therapeutic application thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-7517881-B2 | Triazine derivatives, their preparation and therapeutic application thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-7517881-B2 | Triazine derivatives, their preparation and therapeutic application thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-04-24 | — | — | US | disclosed |
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-04-24 | — | — | US | disclosed |
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-04-24 | — | — | US | disclosed |
| EP-1874761-A2 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | Aventis Pharma S.A. (FR) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111662-A2 | 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTORS | AVENTIS PHARMA S.A. (FR) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | CYP11B2, IL5, TBXA2R | GAA 1439/4885GSK3B 1634/4885FLT3 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.